These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 38076664)
41. Low-dose ketamine infusion in treatment-resistant double depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression. Chen MH; Wu HJ; Li CT; Lin WC; Tsai SJ; Hong CJ; Tu PC; Bai YM; Mao WC; Su TP Hum Psychopharmacol; 2022 Mar; 37(2):e2820. PubMed ID: 34597436 [TBL] [Abstract][Full Text] [Related]
42. Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression. Hilton RC; Rengasamy M; Mansoor B; He J; Mayes T; Emslie GJ; Porta G; Clarke GN; Wagner KD; Birmaher B; Keller MB; Ryan N; Shamseddeen W; Asarnow JR; Brent DA J Am Acad Child Adolesc Psychiatry; 2013 May; 52(5):482-92. PubMed ID: 23622849 [TBL] [Abstract][Full Text] [Related]
48. L-methylfolate Augmentation to Antidepressants for Adolescents with Treatment-Resistant Depression: A Case Series. Dartois LL; Stutzman DL; Morrow M J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):386-391. PubMed ID: 31058543 [TBL] [Abstract][Full Text] [Related]
49. Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults. MacQueen G; Santaguida P; Keshavarz H; Jaworska N; Levine M; Beyene J; Raina P Can J Psychiatry; 2017 Jan; 62(1):11-23. PubMed ID: 27554483 [TBL] [Abstract][Full Text] [Related]
50. Rapid antisuicidal effects of prolonged iTBS on treatment-resistant depression: A case report. Tien Y; Huang CW; Chan CH Psychiatry Res; 2021 Nov; 305():114264. PubMed ID: 34752989 [No Abstract] [Full Text] [Related]
51. Using mechanism of action to choose medications for treatment-resistant depression. Thase ME; Schwartz TL J Clin Psychiatry; 2015 Sep; 76(9):e1147. PubMed ID: 26455685 [TBL] [Abstract][Full Text] [Related]
52. Role of Psychedelics in Treatment-Resistant Depression. Kamal S; Jha MK; Radhakrishnan R Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346 [TBL] [Abstract][Full Text] [Related]
54. [ESKETAMINE FOR TREATMENT RESISTANT DEPRESSION: RESEARCH AND RISK MANAGEMENT]. Marom A; Rosca P Harefuah; 2021 Jun; 160(6):372-376. PubMed ID: 34160154 [TBL] [Abstract][Full Text] [Related]
55. On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression. Gukasyan N Med; 2023 Jan; 4(1):8-9. PubMed ID: 36640755 [TBL] [Abstract][Full Text] [Related]
56. [The use of psilocybin for treatment-resistant depression]. Johannesdottir A; Sigurdsson E Laeknabladid; 2022 Sep; 108(9):403-410. PubMed ID: 36040772 [TBL] [Abstract][Full Text] [Related]
57. Esketamine (Spravato) for Treatment-Resistant Depression. Jalloh M Am Fam Physician; 2020 Mar; 101(6):339-340. PubMed ID: 32163257 [No Abstract] [Full Text] [Related]
58. Treatment-Resistant Depression in Adolescents: Clinical Features and Measurement of Treatment Resistance. Strawn JR; Aaronson ST; Elmaadawi AZ; Schrodt GR; Holbert RC; Verdoliva S; Heart K; Demitrack MA; Croarkin PE J Child Adolesc Psychopharmacol; 2020 May; 30(4):261-266. PubMed ID: 32315537 [No Abstract] [Full Text] [Related]
59. Treatment-Resistant Depression in Older Adults. Steffens DC N Engl J Med; 2024 Feb; 390(7):630-639. PubMed ID: 38354142 [TBL] [Abstract][Full Text] [Related]
60. A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression. McCarthy MJ; Chen Y; Demodena A; Leckband SG; Fischer E; Golshan S; Suppes T; Kelsoe JR J Psychopharmacol; 2021 Aug; 35(8):992-1002. PubMed ID: 33938307 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]